HomeCompareZIOP vs SPHD

ZIOP vs SPHD: Dividend Comparison 2026

ZIOP yields 231.03% · SPHD yields 4.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZIOP wins by $281.97M in total portfolio value
10 years
ZIOP
ZIOP
● Live price
231.03%
Share price
$0.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281.99M
Annual income
$152,307,756.02
Full ZIOP calculator →
SPHD
SPHD
● Live price
4.30%
Share price
$49.61
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$567.37
Full SPHD calculator →

Portfolio growth — ZIOP vs SPHD

📍 ZIOP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZIOPSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZIOP + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZIOP pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZIOP
Annual income on $10K today (after 15% tax)
$19,637.29/yr
After 10yr DRIP, annual income (after tax)
$129,461,592.62/yr
SPHD
Annual income on $10K today (after 15% tax)
$365.92/yr
After 10yr DRIP, annual income (after tax)
$482.26/yr
At 15% tax rate, ZIOP beats the other by $129,461,110.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZIOP + SPHD for your $10,000?

ZIOP: 50%SPHD: 50%
100% SPHD50/50100% ZIOP
Portfolio after 10yr
$141.01M
Annual income
$76,154,161.69/yr
Blended yield
54.01%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZIOP buys
0
SPHD buys
0
No recent congressional trades found for ZIOP or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZIOPSPHD
Forward yield231.03%4.30%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$281.99M$26.5K
Annual income after 10y$152,307,756.02$567.37
Total dividends collected$267.75M$5.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ZIOP vs SPHD ($10,000, DRIP)

YearZIOP PortfolioZIOP Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$33,803$23,102.69$11,130$430.50+$22.7KZIOP
2$109,153$72,984.41$12,357$447.82+$96.8KZIOP
3$337,052$220,258.08$13,687$464.65+$323.4KZIOP
4$996,281$635,635.69$15,126$480.98+$981.2KZIOP
5$2,821,960$1,755,939.31$16,682$496.78+$2.81MZIOP
6$7,667,803$4,648,304.92$18,362$512.03+$7.65MZIOP
7$20,008,593$11,804,044.41$20,174$526.72+$19.99MZIOP
8$50,195,948$28,786,753.46$22,127$540.84+$50.17MZIOP
9$121,203,020$67,493,355.30$24,230$554.39+$121.18MZIOP
10$281,994,987$152,307,756.02$26,493$567.37+$281.97MZIOP

ZIOP vs SPHD: Complete Analysis 2026

ZIOPStock

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Full ZIOP Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this ZIOP vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZIOP vs SCHDZIOP vs JEPIZIOP vs OZIOP vs KOZIOP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.